Consequently, the immune checkpoint blockage (ICB) of NKG2A gene, Monalizumab [28] combined with PANC754 full-length overexpression was applied to the immune therapy of CRC in our translational medical research. This evidence concerns the gene KLRC1 and colorectal carcinoma.